Compositions and methods for treating renal failure

Abstract

The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.

1 - 28 . (canceled) 
     
     
         29 . A method of treating hepatorenal syndrome in a patient in need thereof, comprising administering a pharmaceutical composition comprising angiotensin II to the patient, wherein the angiotensin II is administered at a rate of about 1 ng/kg/min to about 100 ng/kg/min. 
     
     
         30 . The method of  claim 29 , wherein the angiotensin II is administered at a rate of about 10 ng/kg/min to about 80 ng/kg/min. 
     
     
         31 . The method of  claim 29 , wherein the angiotensin II is administered at a rate of about 20 ng/kg/min to about 40 ng/kg/min. 
     
     
         32 . The method of  claim 29 , wherein the angiotensin II is administered at a rate of about 20 ng/kg/min, about 30 ng/kg/min, or about 40 ng/kg/min. 
     
     
         33 . The method of  claim 32 , wherein the angiotensin II is administered at a rate of about 20 ng/kg/min. 
     
     
         34 . The method of  claim 29 , wherein the patient has a serum creatinine level greater than 1.5 mg/dl. 
     
     
         35 . The method of  claim 29 , wherein the patient has a 24-hour serum creatinine clearance of less than 40 ml/min. 
     
     
         36 . The method of  claim 29 , wherein the patient is a human. 
     
     
         37 . The method of  claim 29 , wherein the angiotensin II is administered at a variable rate based on mean arterial pressure in the patient, wherein the mean arterial pressure does not exceed 80 mmHg, 90 mmHg, 100 mmHg, 110 mmHg or 120 mmHg. 
     
     
         38 . The method of  claim 29 , wherein the angiotensin II is administered at a variable rate based on mean arterial pressure in the patient, wherein the mean arterial pressure is maintained between 80 mmHg and 100 mmHg. 
     
     
         39 . The method of  claim 29 , wherein the angiotensin II is administered over a period of time of at least 24 hours or from 8 hours to 24 hours. 
     
     
         40 . The method of  claim 29 , wherein the angiotensin II is administered over a period of time of at least 2-6 days. 
     
     
         41 . The method of  claim 29 , wherein the angiotensin II is administered continuously for 2-11 days. 
     
     
         42 . The method of  claim 29 , wherein the method further comprises testing the patient for a change in a therapeutic parameter and, if the patient has a positive response, administering an additional dose of the pharmaceutical composition to the patient. 
     
     
         43 . The method of  claim 42 , wherein the therapeutic parameter is serum creatinine level, estimated glomerular filtration rate, serum sodium level, serum potassium level, or urine sodium concentration. 
     
     
         44 . The method of  claim 43 , wherein a decrease in the patient's serum creatinine level, urine sodium concentration, or serum potassium level or an increase in the patient's serum sodium level, or estimated glomerular filtration rate is indicative of a positive response to the angiotensin therapy.